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Abstract

ENHANCING ADHERENCE TO PRESCRIBED OPIOIDS USING A MOBILE-BASE
APPLICATION: A PILOT STUDY OF FEASIBILITY IN CHRONIC NON-CANCER PAIN.
By Daniel Mouaffo Sop
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2017.
Major Director: Ding-Yu Fei, PhD, Department of Biomedical Engineering
Nonadherence (overutilization and underutilization) to prescribed opioids underlies the current
us opioid epidemic/crisis. Methods to measure opioid adherence have limitations or are only
proxy measures. Examples of such methods include: patient recall, pill counts, refill rates,
biological monitoring such as urine toxicology, and electronic monitoring such as mems caps.
While not perfect, software programs or apps which collect instantaneous patient reports of
utilization using reminders, and those that have the potential to encourage appropriate
behavior, are gaining popularity as a way to monitor adherence. We were interested to
develop such a software app to monitor opioid adherence. In this study we present feasibility of
a mobile monitoring and reporting system that would provide an accurate unbiased screening
tool to systematically analyze opioid adherence. In addition, the software simultaneously
measures pain.
We developed this mobile-based application, OpPill, for the iOS and Android smartphone
platforms. Development and testing consisted of using existing deep mixed methods research
on pain behavior and opioid use among sickle cell disease (SCD) patients (n=21) to determine
the most effective application content and/or structure. The application was used by sickle cell
disease patients (n=30) at the Virginia Commonwealth University Health System (VCUHS).

xii

The Mobile Applications Rating Scale: a new and validated tool for assessing the quality of
health mobile apps for engagement, functionality, aesthetics, information quality, subjective
quality, relevance and overall impact was administered post usage to evaluate the application.

A total of 28 patients were recruited to review and test the software at one sitting. Patients
were equally divided among males and females, had a high school to graduate level
education, with a majority having some college education. The majority of the population found
the application to be relevant for their care. When surveyed to select all the items they thought
the application was designed to do, 37% indicated that it was aimed at improving their physical
health, and 37% thought it was designed to help them set goals, while 29.6% and 22.2% said
respectively that it helped them feel happy/healthy and reduce negative emotions. In regards
to the targeted population, patients where asked if the content was appropriate for sickle cell
and the majority said it was well-targeted, with negligible issues (88.8%). Study participants
were asked if they would recommend this application to people with sickle cell disease and
100% said they would recommend the application. Patients were also asked to report on the
completeness of information within the app, the majority (96%) reported on the application’s
completeness while 4% estimated the information to be minimal or overwhelming. The quality
of information as it pertains to sickle cell patients was overwhelimingly reported to be relevant
(91.7%); only 8.3% found the application to be poorly relevant to sickle cell disease. The
application’s performance was positively rated at 100% while the ease of its use positively
rated at 91.7%. Most participants (85.7%) found the application to be interesting to use while
74% found it entertaining. All users found the application’s navigation to be logical and
accurate with consistent and intuitive gestural design.
When asked how many times patients thought they would use the application in the next 12
months, results showed 24% would use it over 50 times, 36% would use it somewhere
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between 10-50 times and 40% would only use it 3-10 times. Some patients reported that they
would pay for the application (24%) while 44% said they might pay and 32% reported that they
would not pay for this application. On a scale of 1 to 5 with 1 being the lowest and 5 being the
highest, mean engagement, functionality, aesthetics and information scores were calculated
and yielded the following results: mean engagement score: 3.96, mean functionality score:
4.54, mean aesthetics score: 3.96 and mean information score: 3.91.

We conclude that surveyed patients believe it is feasible to use a smartphone application
specifically targeted to monitor opioid use and behavior in patients with sickle cell disease
(SCD)-associated pain. Results are limited in that these feasibility results are based on a onetime survey of patients shown the software app at one sitting, and not on repeated app use
over time. Future work should include validation via quantifying repeated app use over time, as
well as reported behaviors such as opioid use while using the software app.
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Chapter 1

Introduction
American health literacy is poor. In 2004, the Institute of Medicine’s report on health
literacy estimated that more than 90 million people have difficulty understanding, using
and acting on health information (David Kindig MD, 2004) 1
Prescriptions and prescription errors are common. According to the Patient-Centered
Primary Care Collaborative, more than 3.5 billion prescriptions are written annually in
the United States, and four out of five patients who visit a physician leave with at least
one prescription. Medications are involved in 80 percent of all treatments and impact
every aspect of a patient’s life 2. The Institute of Medicine conducted five separate
studies that placed the rate of medication errors per 100 doses from 2.4 percent to 11.1
percent in inpatient hospital settings 3.
Patient safety and important health outcomes are compromised by poor health literacy,
leading to poor adherence, medication errors by patients, and medication misuse.
According to the International Society for Pharmacoeconomics and Outcome Research
(ISPOR), adherence is “the extent to which a patient acts in accordance with the
prescribed interval, and dose of a dosing regimen”4. Poor adherence causes
approximately 33% to 69% of medication-related hospitalizations and accounts for
$100 billion in annual healthcare costs. 5 Irrespective of disease, medication complexity,
or how adherence is measured, the average adherence rate to chronic medication
therapy is approximately 50%. 6. Medication nonadherence can affect patient health
adversely, negatively impact a patient’s relationship with his/her care provider, skew
results of clinical therapy trials, and increase health resource consumption. 7,8
Mobile health (mHealth), the general term for the use of mobile phones and other
wireless technology in medical care (http://www.himss.org/mhealth), is being sought to
improve prescribing, adherence, patient safety, and health outcomes. Research
1

conducted in 2016 by Park Associates found that more than 10 percent of the nation’s
caregivers are also using mHealth tools to track medications for their charges. That
same study found that almost 30 percent of caregivers would be interested in using
those tools, as would 41 percent of Americans who expect to care for a loved one in the
future 9.
Perhaps nowhere is medication nonadherence more in the news than in opioid
nonadherence, specifically opioid misuse. Currently opioids are prescribed using
conventional intervals, for example, every 4 hours as needed for pain in the case of a
short-acting opioid, and every 12 hours in the case of a long-acting opioid 10. Patients
may deviate from their prescribed specific dosing instructions.
It is well-recognized there is an opioid prescription epidemic in the US. Accordingly, the
CDC has issued guidelines that recommend against the use of high dose opioids11. In
addition, efforts are underway to promote safe opioid use, to improve opioid adherence,
and to prevent prescription opioid diversion by identifying high-risk patients and by
educating patients as well as families regarding the safe use, storage, and disposal of
opioids.
A significant portion of Patients with sickle cell disease (SCD), the most common
inherited blood disorder, use prescribed opioids regularly. SCD affects the hemoglobin
structure of red blood cells such that they form a sickle shape. SCD produces a
progressively disabling illness with severe clinical consequences. Symptoms of SCD
vary but are highlighted by sudden acute unbearable pain throughout the body, known
as crises in addition to profound, hemolytic anemia. A large descriptive diary study of
pain and opioid use in SCD found that opioid use was prevalent including short acting
and long acting. The unbearable and unpredictable pain puts patients with SCD at risk
of being deprived of effective pain management because of the more recent heightened
scrutiny on prescription opioid use. In a study aiming to understand adherence to
opioids in sickle cell disease, results showed that many patients with SCD take their
2

medication differently than instructed on the prescription during and between painful
episodes, both underusing and overusing their opioids, when compared to the
clinician’s instructions12. Because of the high prevalence of opioid use in patients with
SCD, they are often stigmatized as drug-seeking 13. Thus, when using the ISPOR
definition, many SCD patients exhibit medication nonadherence.
Even though SCD is a unique condition as it relates to pain, in many ways it typifies
chronic non-cancer pain. Clinicians who prescribe opioids to patients with chronic noncancer pain must be concerned about the opioid epidemic and about patient safety,
while simultaneously addressing patients’ pain needs.
Currently popular methods to measure adherence, including patient self-reports, pill
counts, refill rates, biological monitoring, and electronic monitoring, have limitations and
are only proxy measures. 14,15,16 Patient self-reports rely on memory and are prone to
inaccuracies and recall bias. 17 Pill counts are unreliable if patients fail to return bottles
or discard pills before the count. Research in Sickle cell disease has shown that
biological monitoring such as urine toxicology screens are not very precise at
quantifying medication use. 18
The use of electronic monitoring devices that detect the opening and closing of a
medication bottle, such as the Medication Event Monitoring System (MEMS), has
shown validity in providing an adequate representation of the complexities of patient
adherence in a trial of patients undergoing remission with ulcerative colitis 19. However,
these devices do not reflect direct medication ingestion, and could be thwarted by
patients attempting to hide overuse or underuse.
Currently, the most reliable way to quantify medication adherence are digital pill or
ingestible biosensor systems. These systems rely on a radiofrequency emitter which
directly measures medication ingestion. A study utilizing a digital pill to Assess RealTime Medication Adherence 20 found the system also was an adequate representationof
patient adherence. But although reliable, this system is impractical for use in SCD.
3

These systems are currently poorly available, still largely experimental, and too
expensive for wide-spread use 21, especially for SCD care, due to the financial
disparities of these patients.
In order to safely start, adjust, taper, and stop opioids, clinicians need to better
understand contextual opioid adherence—just how and under what circumstances their
patients use their prescribed opioids. Ideally, clinicians need to know when a patient
takes the opioid, what dose is taken at the time, and the biopsychosocial and
environmental context around that particular opioid dose. Context should include. the
level of pain that triggered the opioid use, the weather at the time, and momentary
stress surrounding the dose. All are known to affect pain in SCD. 22,23 With a better
understanding of the opioid use pattern and context, clinicians can better identify pain
triggers or exacerbating factors unique to each patient, develop a better individualized
opioid management plan, and more intelligently apply non-pharmacologic interventions
to mitigate pain and opioid use.
To supply this information, mHealth, specifically smartphone applications, offers a
potentially useful technology. mHealth Apps are already widely used for health
improvement in other chronic diseases. For example, current data demonstrate that
electronic mobile devices using reminder systems through traditional means of
telecommunication, like Short Message Service (SMS) text messaging, improve
adherence and behavior and can be useful in measuring adherence 24. One study found
that teenagers with asthma who used a specialized system to create and schedule
personal text message reminders gave the system high ratings for acceptability, ease
of use, and usefulness; however, asthma control was not impacted 25. Further, in a
study to help control blood glucose levels in patients with diabetes using a
comprehensive, Web-based education system and cellular phone access, the
frequency of accessing the eMOD (electronic Management of Diabetes) software was
significantly correlated to the change in glycosylated hemoglobin levels 26.
4

mHealth can offer numerous special techniques for helping patients take their
medications given their customizable content, affordability and portability. Furthermore,
with a medicinal services industry seeing non-adherence rates of as high as 50 percent
and yearly expenses of between $100 billion and $300 billion, the potential return on
investment from utilizing cell phone adherence applications could potentially outweigh
the burden of non-adherence. This accessible innovation offers numerous highlights
that can enable patients and healthcare providers in improving medication taking
behavior.
Thus, the goal of our project was to develop and test the acceptability and usability of a
mobile software application among adult patients with Sickle cell disease (SCD) to
increase adherence to prescribed Opioids. Additionally, the application would allow
them to report context-specific data surrounding their medication intake behavior, selfreported pain and Vaso-Occlusive crises.

5

Chapter 2

Literature Review
I.

Sickle Cell Disease and Pain

(Samir K. Ballas, 2012)

27Many

individuals with SCD experience daily pain, which

affects all aspects of life. There is great variability in the rate of recurrence and severity
of pain in a SCD patient’s experience. Acute and/or chronic pain may be hard to
tolerate and mentally exhausting. Furthermore, this pain may limit the quality of life of
patients’ daily activities. Additionally, the constant pain is significantly associated with
depression, anxiety, cognitive development, weight loss, disturbance in sleep, mood
swings and distorted communication, and possibly loss of employment and productivity.
Moreover, mistrust from other patients, caregivers, family members, and friends may
lead to negative psychological effects28.
II.

Opioid analgesics in pain management for sickle cell pain

(I Boyd, 2014)29Prescription opioids minimize the chronic disease pain by providing
pain control to SCD patients. Thus, opioid analgesics are the most commonly accepted
method of pain management for sickle cell. Chronic and acute opioid treatment have
been accepted as a suitable and effective method in pain management. Many studies,
theories, and anecdotes demonstrate clinically significant pain relief from stable doses
of opioid medication. Reduced length of hospital stay and reduced resource use of
health care systems result from effective pain management and mobility. At-home pain
relief using “as-needed” (PRN) analgesics for severe sickle cell pain is common;
however, long-acting “scheduled” medication is more effective and could provide more
consistent pain relief, generate less euphoria upon administration, allow slower
development of tolerance, and offer more favorable side-effect profiles than shortacting counterparts. Many of these individuals with SCD manage pain at home using
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prescribed opioid analgesics, which have been found to give significant pain relief when
used appropriately 30.
III.

Opioid use in sickle cell disease is controversial

(T.R. Kotila, 2015) 31Opioid use in sickle cell disease (SCD) is controversial. SCD
patients may distrust physicians and exhibit pseudo-addiction behaviors, including
hoarding and going to several physicians to acquire more medication. As with other
patients using prescribed opioids, SCD patients may become addicted or manifest
criminal behavior with opioid use, although this is a rare occurrence. A few studies
regarding long-term opioid use in SCD patients have been published 32, but an in-depth
analysis of how and why SCD patients use prescribed opioids on a daily and
continuous basis has not been done.
These prescription opioids are often under-prescribed due to physicians’ reluctance to
prescribe adequate dosages of opioid analgesia and concerns about addiction,
tolerance, and side effects 33 .Physicians tend to overestimate the prevalence of opioid
dependence in patients with sickle cell crises despite a low 3% incidence of opioid
analgesic addiction and may even harbor negative attitudes towards SCD patients in
general 34. Nevertheless, the recent rise in prescription opioid use for cancer and noncancer pain management remains controversial due to widely divergent perspectives
and evidence regarding inadequate and unnecessary treatment of pain. Over the last
two decades, the proportion of office visits in which prescriptions for potent opioids
were given increased from 2% to 9% 35. Despite this rise in rate of opioid prescription
and use, there is still a significant data showing inadequate pain management 36.
To address this gap in the pain management literature for SCD and perhaps relevant to
opioid use in non-cancer, chronic pain disorders, there is a need to explore how and
why patients use their prescribed opioids.
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IV.

Momentarily Biopsychosocial-Spiritual (BPSS) Reasons

(Lou Ella V. Taylor, 2014) 37Research on opioid use has not yet focused on time- or
context-specific use of opioids and motivation to deviate from prescribed opioid
regimens. In part, this is due to the irreducible nature of pain. Several models have
been created to describe the nature of pain; one of the most prominent models is the
Biopsychosocial Model, which divides pain into biological, psychological, and social
components. Some researchers consider spirituality another component of pain
management due to the nature of religious and spiritual coping methods many chronic
pain sufferers utilize. The Biopsychosocial-Spiritual (BPSS) model when describing
reasons behind different methods of opioid medication use in sickle cell disease
because chronic pain in adults with sickle cell disease (SCD) is a complex
multidimensional experience that includes biological, psychological, sociological, and
spiritual factors.
V.

Why adherence to prescribed opioid in SCD?

(Alsalman AJ 1, 2013)38Despite wide-spread acceptance in the use of opioids for
chronic, non-cancer pain, there is a concern for the possibility of abuse, misuse, and
diversion. In order to resolve this controversy, we must explore the motivation for
patients to experience adequate pain control versus any adverse effects and the
potential for abuse. It is important to evaluate medication-taking behaviors, including
adherence to an established regimen, normal non-adherence to that daily regimen, and
any aberrant behavior.
However, use of opiates is controversial due to its side effects and risk of addiction.
Distrust from physicians and peers may lead some SCD patients to improperly use
opioids and exhibit pseudo-addiction behaviors, leading to discord between healthcare
providers and SCD patients. This indicates the need for effective pain management, in
particular, research analyzing the motivations behind opioid use.
8

Despite the pain and medication adherence models in the literature, current models fail
to capture time- or context-specific use of opioids. The unpredictable and severe nature
of SCD pain crises as well as the conventional use of short-acting (and sometimes
long-acting) opioids in the SCD patient population presents as an ideal disease
paradigm in which patterns of opioid usage and adherence may be studied. Also,
despite nearly a century of common use of opioids to treat pain, there is surprisingly
scarce research on improving adherence to prescribed opioid in non-cancer pain and
the relationship between this pain and opioids intake. Additionally, patterns underlying
opioid use under specific contexts (environmental, emotional) such as those in most
BPSS phenomena have not yet been tested. Alsalman AJ (1, 2013) used a confidential
mixed-methods study where short surveys were utilized to quantitatively examine
patterns of adherence (or nonadherence) motivations with qualitative exploration of
these reasons for a more comprehensive analysis.
VI.

Smartphones, Applications and Medicine

(Lindsey Dayer, 2013)39With the increased adoption of smartphones, there has been a
simultaneous explosion of health focused mobile applications. A report from the IMS
Institute for Healthcare Informatics counted over 165,000 healthcare apps available for
download, many of which can be used to improve adherence for patients taking daily
medications.
Medication nonadherence is a significant barrier to disease management, with
estimates of nonadherence ranging from 25% to 50% depending on factors such as
disease, insurance coverage, and patient characteristics. Medication nonadherence
also affects health outcomes and healthcare costs. The US spends $100-$300 billion
annually on avoidable health care costs due to nonadherence 40. In response to the
costs and poor health outcomes, various tailored interventions have been developed
and tested to improve poor medication adherence including electronic pill boxes, text
9

messaging, online interventions (such as assessments), and counseling. However,
despite these efforts, we still need additional tailored and effective tools to improve
adherence 41.
The prevalence of smartphone usage has dramatically increased over the past several
years. Presently, 77% of US adults own a smartphone, which is a big jump from the
35% who owned a smartphone in 2011. With smartphone use on the rise, Dayer and
colleagues published a 2013 article about the potential benefits of mobile apps:
they are relatively inexpensive, easily accessible, and available 24/7. These software
interface can provide tailored reminders (both for dosages and refills), and can function
as a repository for medication and user-specific information. 42
Medication management and adherence doesn’t just affect patients and their
doctors. Research conducted in 2016 by Park Associates found that more than 10
percent of the nation’s caregivers are also using mHealth tool to track medications for
billing purposes. That same study found that almost 30 percent of caregivers would be
interested in using those tools, as would 41 percent of Americans who expect to care
for a loved one in the future 43.

10

Chapter 3

Methods
I. A rationale
Although reliable and top of the line systems such as MEMScaps and Biosensor
ingestible pills exist and can provide close to or real-time adherence information, their
implementation for sickle cell disease care as a method for measuring adherence is
virtually impossible for several reasons. The first and main reason being the disparities
that surround Sickle Cell disease and the population it affects. For example, the funding
disparities for research on sickle cell compared to other pediatric diseases are very
large. Cystic fibrosis, a disease that affects primarily Caucasians, occurs in only a third
of the numbers affected by SCD, but received 3.5 times more NIH funding. Private
funding from foundations was about 400 times higher for cystic fibrosis 44.The disparities
associated to Sickle cell Disease are not limited to SCD care, research or funding. The
debilitating aspect of the disease and the unpredictability of onset for associated vasoocclusive crisis severely limits SCD patients’ ability to secure and maintain gainful
employment thus causing reliance on government subsidized programs, decreased
quality of care and decreased quality of life 45 . These programs such as Medicare,
Medicaid and other disability programs have reimbursement and category limits which
would exclude Ingestible Biosensor and MEMScap implementation. The above noted
adherence monitoring systems burden of costs would become patients’ responsibility, a
responsibility that could not be met due to their inability to secure and maintain gainful
employment. Furthermore, there are challenges associated with the use and
implementation of MEMScaps and ingestible sensors. In a study aiming to understand
the challenges of using MEMScap, results show that acceptance of this technology
proved difficult, as many patients either declined upfront or dropped out because they
did not want to use the MEMS. Outcome of the final survey indicated, 41% found
11

transferring medication into the MEMS bottle difficult and 27.2% reported that the
MEMS was a burden and/or difficult to transport. Another 22% of the patients reported
that using the MEMS changed their routine, and 10.2% worried about missing their
medications 46. Ingestible biosensor also known as the digital pill is a newly FDA
approved technology that records when a dose has been taken via electronic signals
sent to a wearable patch (and then, to a smartphone), via a safe-for-consumption
sensor inside the pill. Although the generated data is objective, this technology would
incur high costs that SCD patients may not afford and raises several new questions and
concerns such as privacy and HIPPA related concerns. Ingestible technology will put
meaningful statistics and metrics in front of patients and doctors, in real time, from
anywhere in the world. Arlyn Scales also highlights the fact that we don't know exactly
what would happen if it malfunctioned, and the only way to find out is to use the
technology. It's tricky, however, because the stakes are higher for a medical tool than if
an iPhone dies or malfunctions 47. Data from previous studies demonstrate that
electronic mobile devices using reminder systems through traditional means of
telecommunication, like Short Message Service (SMS) text messaging, improve
medication adherence and patient behavior and can be useful in measuring adherence
in the short term 48. Investigators determined that sending photographs of medication
capsules through cellular phones before ingestion provided more accurate time
measures of adherence 49. One study found that teenagers with asthma who used a
specialized system to create and schedule personal text message reminders gave the
system high ratings for acceptability, ease of use, and usefulness; however, their
asthma control was similar to baseline 50. In a study using a comprehensive, Webbased education system cellular phone access to help control blood glucose levels in
patients with diabetes, the frequency of accessing the eMOD (electronic Management
of Diabetes) system through a cellular phone was directly related to the change in
glycosylated hemoglobin levels 51. Although a systematic review of Internet-based
12

adherence interventions found promising results, it also found that the 13 studies
lacked quality measurements of adherence 52. Various studies of the use of
smartphones in the clinical setting have been performed 53, but studies empirically
testing smartphone apps acceptability in chronic pain with aims to improve adherence
are lacking. Thus, the rationale behind our study design.
II. Specific Aims
-

To develop an Electronic Data Capture platform using the OpPill mobile
application to capture context-specific data associated with prescription opioid
use.

-

To test the acceptability and usability of the OpPill mobile application among
adult patients with Sickle cell disease (SCD) to report context-specific data.

III. Study Design
The OpPill mobile application (app) was designed and built to contain the following
design features: (1) An opioid use diary to allow the user to report (a) the type of opioid
used, (b) the dose taken, (c) the time the medication was taken, and (d) context specific
information associated with the opioid use (2) A pain diary to allow the user to report (a)
pain intensity levels, (b) the time pain intensity is being experienced and (c) context
specific information associated with the pain intensity level. (3) The ability for
researchers to monitor and track pain level, opioid use, and context-specific information
overtime. (4) The ability for the research team to communicate and provide feedback
to the user. (5) The ability for the application to alert the research team of various
conditions such as (a) the user’s failure to access the application within a specified
period of time, and (b) if opioid use exceeds a specified dose amount over a specified
period of time.
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1) Phase 1: Focus Groups
Phase 1 conducted by another researcher involved the recruitment of 21 patients for
individual interviews to gain knowledge about sickle cell patients’ typical contexts and
activities reported associated with their pain and opioid use. The results of this work
(Abdulkhaliq J. Alsalman, 2013) reported the following: population studied consisted of
52% (n=11) men and 48% (n=10) women with a mean age of 36 years, ranging from a
diverse background of socioeconomic and educational levels. Medical history and
psychological variables were assessed at baseline time. Relevant medical history
predictors included history of pain days and history of analgesics medications54. This
multi-phase mixed method study described the opioid taking behavior and the reasons
for adherence to prescribed opioid of 21 SCD patients in the Adult Sickle Cell Anemia
Clinic at Virginia Commonwealth University Health System (VCUHS) in Richmond,
Virginia. Adherence was described and assessed by the investigator following an
extensive semi-structured interview and preliminary survey regarding adherence
behavior. The investigator used 24 questions in an open-ended, face-to-face interview
and preliminary survey to collect data about adherence to the prescribed opioid
regimens. Qualitative thematic analysis uncovered several patterns of opioid-taking
behavior and several related biopsychosocial-spiritual phenomena. These patterns and
phenomena portrayed a new six-domain conceptual framework that addresses the
complex individual, relational, environmental, cultural, and systemic issues surrounding
opioid taking-behavior in SCD. From this six-domain framework, the investigator
organized the explanatory factors into a new method of classification, which included
two overarching domains: intra-patient (biological, psychological, spiritual), extra-patient
(social support, provider relationships, institutional norms, culture, legal and
governmental policy). This classification provided a roadmap for future research that
led to phase 2 of our project. The six domains explored in the research offered
guidance towards understanding a complex explanation of the effect of pain, its
14

pharmacotherapy, and medication taking behaviors on an individual’s health that
simultaneously bridges all healthcare domains. The context themes and activity themes
that emerged were programmed as pre-populated lists into the application.
2) Phase 2: Prototype Development
Phase 2 of the research study involved actual software application development. The
OpPill application was developed to be accessible using an IOS or android powered
device. The application was built using client-server architecture. The client component
was built in native SWIFT code and the server component using Google Cloud Next
Enterprise server to broker data exchange. The system contains a password-protected
Web-interface allowing safeguards to protect users while enabling researchers the
ability to create studies, add new study participants, and access results. Data entered
by participants regardless of the device used will be transmitted to the server using an
encrypted (HTTPS) protocol over a Secure Socket Layer (SSL) connection. The server
was hosted on the Google Cloud behind a firewall in a network secure environment. A
username and password was required to access data on the user end and the
researcher’s end. Following the development of the OpPill prototype, feedback was
obtained, and a subsequent final model was built based on the feedback provided.
Suggested recommendations were addressed before proceeding to high-fidelity testing.
3) Phase 3: Low-Fidelity Testing
Following the development, the app was trialed with SCD adults to determine the
application content and/or structure’s accuracy and appeal. The application was also
demonstrated to experienced SCD clinicians for content validity evaluation and clinical
significance. Input received from patients and clinicians was included in the final
phases of the application’s development.
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4) Phase 4: High-fidelity Testing
Phase 4 involved applying the application developed to additional evaluation for its
Usability, Clinical Feasibility and Compliance (High fidelity User-Centered Design
parameter). This was done through an approved Institutional Review Board application
to assess the application’s quality at the Sickle Cell Clinic within the VCU Ambulatory
care center using a Cross-sectional cohort design. We recruited a purposive,
heterogeneous sample of 30 adult SCD patients for this study.
Patients were asked to use the application during their clinic visit recording their own
pain, opioid use, and circumstances surrounding their input while accessing the
application for engagement, functionality, aesthetics, information quality, and subjective
quality. At the end of each user’s trial, The Mobile Application Rating Scale (MARS), a
newly validated tool was used to assess patient’s feedback regarding the app (See
Appendix); notably: Engagement, Functionality, Aesthetics, Information accuracy,
Subjective Quality, and Perceived Impact. Responses were evaluated to explore
emerging themes and field notes on 1) ease of app use, 2) general endorsement of the
app (i.e. The features of the app whether it is appealing to adults with SCD or not), 3)
rewarding and trust building aspects of the app, and 4) recommendations for improving
the user-interface of the app. The MARS tool was first published in 2015 explaining the
process used for its development and validation, thus its rarity. The MARS tool
development involved a comprehensive literature search to identify articles containing
explicit Web- or app-related quality rating criteria. English-language papers from
January 2000 through January 2013 were retrieved from PsycINFO, ProQuest,
EBSCOhost, IEEE Xplore, Web of Science, and ScienceDirect. The search terms were,
“mobile” AND “app*” OR “web*” PAIRED WITH “quality” OR “criteria” OR “assess*” OR
“evaluat* 55”. Per Stoyanov, criteria for the assessment of app quality were categorized
by an expert panel to develop the new Mobile App Rating Scale subscales, items,
descriptors, and anchors. Derivation of the MARS tool involved selecting 10 apps from
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a sample of 60 apps that were randomly selected using an online randomizer. The 10
Applications were used to pilot the MARS rating procedure and the remaining 50
Applications provided data on irater reliability.
IV. Assurance of Access to Patient Sample
For pilot studies, a sample size in the range of 10 to 20 subjects is sufficient for
feasibility assessments. 21 patients participated in phase1 and 30 patients in phase 4.
Adults SCD subjects came from a mixture of the (Pain In Sickle Cell Epidemiologic
Study) PiSCES and (Start Healing In Patients with HydroxyUrea) SHIP-HU cohort but
were enriched by new adult SCD patients. Patients in this cohort met conceptually
either the American Pain Society definition or the International Association for the Study
of Pain’s definition of chronic pain.
V. Data Collection
We collected participants demographics and Pain Characteristics to include age, race,
gender, education (highest completed) and self-reported income (in categories).
Opioids adherence and disease characteristics were also collected in the form of
phenotypic manifestation of pain and patient’s disease genotype. Acceptability,
Usability and efficacy of the OpPill was tested using the validated Mobile Application
Rating Scale (MARS) tool. The MARS tool was designed by a research team involved
in the development and validation of eHealth and mHealth interventions, or ‘eTools’55.
The scale aimed to provide researchers, clinicians and developers with a list of
evaluation criteria, and a gradient response scale for their objective evaluation. There
are three main MARS factors: 1, the MARS mean; this is the mean of four objective
subscales (Engagement, Functionality, Aesthetics, and Information). 2, Subjective
Quality. 3, Perceived Impact. Subjective Quality and Perceived Impact are based on
the rater's’ own impression of the eTool, including its usability and perceived
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effectiveness. Additionally, alternative pain quenching practices along with body
temperature at the time of collection was captured.
VI. Data and Safety Monitoring
The research involved no more than minimal risk to the subjects. All patient data were
de-identified. Patient medical records were used partly to pre-screen patients for
eligibility. As part of conditions for treatment, patients sign authorization for this use. All
de-identified information was maintained in a HIPAA-compliant manner.
VII.Institutional Data and Safety Monitoring Board
The VCU IRB served as the institutional review board for this study.
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Chapter 4

Analysis
Characteristics and demographics of patient participants were determined using simple
descriptive statics, as was the mobile application rating scale. The application’s quality
criteria were clustered within the engagement, functionality, aesthetics, information
quality, and subjective quality categories. The subjective qualities were customized to
be sickle cell disease specific in order to relate to the patient population that was
evaluating the OpPill application. Each MARS item used a 5-point scale (1-Inadequate,
2-Poor, 3-Acceptable, 4-Good, 5-Excellent), descriptors for these rating anchors were
written for each item. In cases where an item may not be applicable for all apps, an
option of not applicable was included.
Following the MARS tool guidelines, scores were obtained by individually computing
the mean scores for engagement, functionality, aesthetics, and information quality.
Additionally, an overall mean app quality total was calculated. Mean scores instead of
total scores are used because an item can be rated as not applicable. Additionally,
mean scores are used to provide quality ratings corresponding to the familiar format of
star ratings. The subjective quality sickle cell specific items were analyzed separately
by computing the mean and applying the CORR procedure to evaluate the correlation
of demographics, engagement, function, aesthetics and information with SCD
outcomes of the OpPill application. The MARS app classification section was analyzed
using simple statistics for descriptive purposes only.
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Chapter 5

Results
I. Patient Population: Focus group and Low Fidelity testing – Phase 1
Study participation consisted of a one-time, approximately 1.5 hour in-person interview
using interview guide (see Figure 1). The interviews were audio-recorded and
subsequently transcribed for qualitative analysis. Among other inclusion and exclusion
criteria, eligible subjects were to be between the ages 18 and 65 years, Having SCD
diagnosis, African-American patients and feeling pain for > 30% of days in the last
month. All recruited subjects have received opioid outpatient prescriptions within the
previous 12 months.
Qualitative thematic analysis revealed three phenomena: 1) SCD patients exhibited
various opioid-taking behavior patterns including adherence, overuse, underuse, and
erratic use; 2) Several biopsychosocial factors hindered or motivated opioid use: severe
pain intensity, side effects, stress, family gatherings, unplanned meetings, religious
attendance, and anticipatory fear adverse outcomes; 3) Behaviors varied based on the
time of day, week, month, or year, and also based on the momentary contexts at times
of actual and projected doses. Approximately 57% (n=12) of the participants were
women. Patients ranged in age from 18 to 58 years. Of the 21 patients, 5 (24%)
participants were married. More than half (57%) of the participants have the SS
genotype of SCD. While approximately one-third (33%) of the participants have the SC
genotype of SCD. When asked about rating their pain intensity on the average in last
30 days, the mean reported pain intensity was 5.5 (SD=1.7). A higher proportion (62%)
of the study reported more than >50% of pain days in the last 30 days. More than half
(52% (n=11)) of the participants were on both long-acting and short-acting prescribed.
Notably a higher proportion (62%) of the participants have either college or some
college education. Approximately 57% of the sample reported their income to be in the
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range of $0 to $25,000. Approximately 24% of the patient samples are smokers.
Similarly, around 24% of sample reported drinking alcohol. The interview was added
below in appendix 1 and demographics representing the patient population is
summarized in table 1 below.

Table1: Phase 1 demographics and Other Characteristics for Respondents
Variables
Age Mean (SD)
Gender
Female
Marital Status
Married
Education
High school or less
College or some college
Family income
$ 0 to $25,000
$25,001 to $50,000
$50,001 and Over
Pain Days
≥ 30-50 days
>50 days
Average Pain intensity (1-10)
Mean (SD)
Prescribed Opioid Regimen
Short-acting (PRN) Only
Both short- and long-acting
Drink Alcohol
Yes
Smoke Cigarette
Yes

Frequency (%)
n = 21
35.4 (11.4) years
57%
24%
38%
62%
56%
19%
25%
38%
62%
5.5 (1.7)
52%
48%
24%
24%

21

Figure 1: Developing the interview guide

II. OpPill Application Development Phase 2
The application was designed to reflect the needs and allow for input related to
recurring topics gathered from phase 1. The Application was designed to be
implemented for android and apple smartphone devices. The application was built
using rapid prototyping techniques. The application’s screenshots for both the prototype
and final product are presented in figure 2 and 3 below. A wireframe of the final product
is shown below in figure 4.
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Figure 2: Prototype Screenshots
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Figure 3: Final Application Screenshots
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Contact Us Page

Figure 4: OpPill application Wireframe

III. Phase 3: Low Fidelity Testing
Following the development, the app was trialed with adults SCD caregivers to include
clinicians, social workers, patient navigators, and pharmacy personnel for feedback
regarding the application’s appearance, content validity and flow of information.
Suggestions were made to improve the application’s fluidity, to break down the
anatomical body image into body sections for clarity, to make the application more
engaging, to improve the application’s responsiveness, to improve dull coloring, to add
provider information collection functions and personal medications information
collection functions. The above noted feedback was verbally collected in an open
conversation manner and no formal structure. These recommendations were taken into
consideration and implemented in last iteration of the application’s development.
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IV. Study Participants Phase 4
Patients’ ages ranged from 18.77 to 58.83, with a mean of 36.56 years. Overrall 46.4
%( 13) participants were males whereas 53.6 %( 15) were females. 2 patients were
withdrawn the sample due to acute onset of Vaso-Occlusive crisis. A ranking of
participant’s education showed that 25%(7) had completed an education equivalent to
that of a high school graduate or a GED equivalent, 39.3%(11) had completed some
college, 14.3%(4) had completed a degree equivalent to that of a 2year college,
7.1%(2) had completed a 4-year degree and 14.3%(4) had completed a master’s
degree. None of the participants had completed a doctoral or professional education.
Income representation was spread from <$10,000 (25%), $10,000 to $19,000(29.2%),
$20,000 to $29,000(12.5%), $40,000to $49,000(12.5%), $50,000 to $59,000 (4.2%) to
≥$60,000 (4.2%). Sickle cell patient’s genotypes represented in the study were as
follows: Hemoglobin SS 26.9%(7), Hemoglobin SC 42.3%(11), Hemoglobin S β0
Thalassemia 11.5%(3), Hemoglobin S β+ Thalassemia 3.8%(2) and 15.4% where not
sure of their genotypes at time of the study.
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Table 2: Phase 4 study population demographics
Population Demographics
Gender

N

Frequency (%)

Male

13

46.4

Female

15

53.6

N

Frequency (%)

<HS

0

0

HS/GED

7

25

Some College

11

39.3

2-yr College

4

14.3

4-yr College

2

7.1

Master's

4

14.3

Doctoral

0

0

Professional

0

0

N

Frequency (%)

<10,000

6

25

10,000-19,000

7

29.2

20,000-29,000

3

12.5

30,000-39,000

0

0

40,000-49,000

3

12.5

50,000-59,000

1

4.2

≥60,000

4

16.7

N

Frequency (%)

Hemoglobin SS

7

26.9

Hemoglobin SC

11

42.3

Hemoglobin S β0 Thalassemia

3

11.5

Hemoglobin S β++ Thalassemia

1

3.8

Don't Know

0

0

Not Sure

4

15.4

Other

0

0

Education

Income

Genotype
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IV. Application Classification
After allowing patients to use the application post consenting, two focus questions were
asked to gauge their understanding of what the application was design to do and
reason why the study was being conducted. This was kept in the MARS tool to gather
information regarding topics that would gain the most traction in the design aspect of
the application and the mean of delivery or approach with any future application as it
pertains to the reason for conducting the research. Please note that participants could
select more than one answer for each question. Results indicated the majority believed
the application to have been designed to help them set goals (37%), to improve their
physical health (37%), to help them feel happy and healthy (37%) and to reduce
negative emotions (22.2%). These are the general themes that fall under the rationale
driving this project indicating that our participants had a general understanding of what
the application what being built for. We expected there to be a relatively high percent of
patients selecting behavior change as one of the reasons for building the application,
however the observed results were a mere 3.7%. The complete distribution for this
question was summarized in graph 1 below.
We also gauge participants understanding of the reason why the research study was
being conducted to evaluate their understanding of the study for which they had just
consented to participate in. The vast majority (77.8%) reported that this study was
conducted to obtain feedback regarding the application which satisfied our
expectations. The next ranking response was education/information which can be
explained given that we are aiming to empower patients by getting them involved in
their care. The complete distribution was summarized in graph 2 below.
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Graph 1: Focus – Understanding the design of the app
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Graph 2: Focus – Understanding the reasoning behind the research study
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V. MARS tool Scores
The app quality criteria were clustered within the engagement, functionality,
aesthetics, information quality, and subjective quality categories, to develop 23
subcategories from which the 23 individual MARS items were developed. Each
MARS item used a 5-point scale (1-Inadequate, 2-Poor, 3-Acceptable, 4-Good, 5Excellent), descriptors for these rating anchors were written for each item and
results summarized in table 3 and table 4. A copy of the Mars tool was provided in
appendix 3.

Table 3: MARS tool category scores
Variables

N

Engagement

27

Functionality

Mean

Min

Max

Std Dev

3.93

3

5

0.73

3.64

4.22

24

4.54

3

5

0.66

4.26

4.82

Aesthetics

25

3.92

3

5

0.81

3.59

4.25

Information

22

3.91

2

5

0.87

3.53

4.29

Graph 3: MARS Score Chart
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Sample Size

Mean

MARS Score Chart

CI -

CI +

1) Engagement
Engagement was gauged by assessing the application’s ability to be fun, interesting,
customizable, interactive (e.g. sends alerts, messages, reminders, feedback, enables
sharing), and well-targeted to audience. Although not vigorously found to be
entertaining the overwhelming majority found the application to be well targeted,
interactive and customizable. Results are summarized and represented in table 4 and
graph 4.
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Table 4 – Application Engagement scores

SECTION A
Engagement – fun, interesting, customizable,
interactive (e.g. sends alerts, messages, reminders,
feedback, enables sharing), well-targeted to audience
Entertainment: Is the app fun/entertaining to
use
Dull, not at all
Mostly Boring
OK, for brief time
Moderately
Highly
Interest: Is the app interesting to use?
Dull, not at all
Mostly Boring
OK, for brief time
Moderately
Highly
Customization: Does it provide/retain all
necessary settings/preferences for apps
features (e.g. sound, content, notifications,
etc.)?
Doesn't Allow
Insufficient
Basic
Numerous Options
Complete Tailoring
Interactivity: Does this app allow user input,
provide feedback, contain prompts (reminders,
sharing options, notifications, etc.)?
None
Insufficient
Basic
Variety
Very High
Target group: Is the app content (visual
information, language, design) appropriate for
sickle cell patients?
Completely inappropriate
Most inappropriate
Acceptable
Well-targeted
Perfectly targeted
A. Engagement mean score =
31

N
5
2
11
6
3
N
2
2
4
9
11

Frequency
18.5
7.4
40.7
22.2
11.1
Frequency
7.1
7.1
14.3
32.1
39.3

Counts
0
2
8
7
9

Percent
0
7.7
30.8
29.6
34.6

N
0
0
7
10
8

Frequency
0
0
28
40
32

N
0
0
3
12
12
3.93

Frequency
0
0
11.1
44.4
44.4

Table 5: Section A – Mean Engagement Score

Sample Size

Graph 4: plot- MARS mean engagement score

Scores

2) FUNCTIONALITY
The application’s functionally was assessed by asking patients to report on the app
functioning, ease to learn, navigation, flow logic, and gestural design of app. On this
topic results indicated that majority of patients found the application to be easy to use
and learn, to perform as intended and easy to navigate. Results summarizing patients’
report on application functionality were summarized and graphed in table 5 and graph
5.
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Table 6: Application functionality scores
SECTION B
Functionality – app functioning, easy to learn,
navigation, flow logic, and gestural design of
app
Performance: How accurately/fast do the app
features (functions) and components
(buttons/menus) work?
Broken
Some functions work
Works Overall
Mostly Functional
Perfect/timely response
Ease of use: How easy is it to learn how to use
the app; how clear are the menu labels/icons
and instructions?
No/limited Instructions
Useable after a lot of time/effort
Useable after some time/effort
Clear Instructions
Simple
Navigation: Is moving between screens
logical/accurate/appropriate/ uninterrupted; are
all necessary screen links present?
Difficult
Useable after a lot of time/effort
Useable after some time/effort
Easy to use
Perfectly clear
Gestural design: Are interactions
(taps/swipes/pinches/scrolls) consistent and
intuitive across all components/screens?
Completely Inconsistent
Often Inconsistent
OK w/ some inconsistencies
Mostly consistent
Perfectly consistent
B. Functionality mean score =
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N
0
0
5
7
12

Frequency
0
0
20.8
29.2
50

N
0
1
1
9
13

Frequency
0
4.2
4.2
37.5
54.2

N
0
0
2
5
17

Frequency
0
0
8.3
20.8
70.8

N
0
0
3
9
12
4.54

Frequency
0
0
12.5
37.5
50

Table 7: Section B – Mean Functionality Score

Sample Size

Graph 5: plot- MARS mean functionality score

Scores

3) Aesthetics
Application aesthetics were assessed by asking patients to rate questions regarding the
app’s graphic design, overall visual appeal, color scheme, and stylistic consistency.
Although 2 people indicated that the application did not look good and one patient
reported that the application had a bad design, the majority found the application’s
layout to be satisfactory, clear or professional. Most people found the application’s
graphics to be of good quality and to have high visual appeal. Results were
summarized in tabled 6 and graph 6.
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Table 8: Application Aesthetics Scores
SECTION C
Aesthetics – graphic design, overall visual appeal, color
scheme, and stylistic consistency
Layout: Is arrangement and size of
buttons/icons/menus/content on the screen
appropriate or zoom able if needed?
Very bad design
Bad Design
Satisfactory
Mostly Clear
Professional
Graphics: How high is the quality/resolution of
graphics used for
buttons/icons/menus/content?
Very poor
Low quality
Moderate Quality
High Quality
Very High Quality
Visual appeal: How good does the app look?
None
Little
Some
High
Very High
C. Aesthetics mean score =

Table 9: Section C – mean Aesthetics Score

35

N
0
1
3
12
9

Frequency
0
4
12
48
36

N
0
8
5
10
7
N
1
1
9
8
6
3.92

Frequency
0
8.3
20.8
41.7
29.2
Frequency
4
4
36
32
24

Sample Size

Graph 6: plot- MARS mean aesthetics score

Scores

4) Information Quality
The application’s quality of information was rated by participants through questions
asking them to rate the content for accuracy, quality, quantity, goals and understanding.
Mean scores were calculated and indicated that the majority found the information to be
of high quality. Results were summarized and graphed in table 7 and graph 7.
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Table 10: Application information quality scores
SECTION D
Information – Contains high quality information
(e.g. text, feedback, measures, references)
from a credible source. Select N/A if the app
component is irrelevant.
Accuracy of app description (in app store):
Does app contain what is described?
Misleading
Inaccurate
OK
Accurate
Highly Accurate
Goals: Does app have specific, measurable and
achievable goals (specified in app store
description or within the app itself)?
N/A
App has no chance
Very little chance
OK
Likely
Highly likely
Quality of information: Is app content correct,
well written, and relevant to Sickle Cell disease
?
N/A
Irrelevant
Barely relevant
Moderately relevant
Relevant
Highly relevant
Quantity of information: Is the amount of
information in the App complete?
N/A
Minimal
Insufficient
OK
Broad Range
Comprehensive
Visual information: Can you understand the
images displayed within the App?
N/A
Complelely unclear
Mostly unclear
OK
Mostly clear
Perfectly clear
D. Information mean score =
37

N
0
0
3
14
7

Frequency
0
0
12.5
58.3
29.2

N
2
0
3
8
7
4

Frequency
8.3
0
12.5
33.3
29.2
16.7

N
1
0
1
5
7
10

Frequency
4.2
0
4.2
20.8
29.2
41.7

N
0
1
0
7
10
7

Frequency
0
4
0
28
40
28

N
0
0
0
3
7
15
3.91

Frequency
0
0
0
12
28
60

Table 11: Section D – Mean Information Score

Sample Size

Graph 7: plot- MARS mean information score

Scores
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5) Sickle Cell Specific and Awareness – The CORR procedure
In an effort to better understand the feedback provided by the patients, we applied the
CORR procedure to evaluate the relationship between demographic information, sickle
cell specific responses and the MARS classifications (engagement, functions,
aesthetics and information quality) as it relates to the application.
The CORR procedure computes Pearson correlation coefficients, three nonparametric
measures of association, and the probabilities associated with these statistics. Prior to
analysis, a Simple statistic table is generated alongside with a variable table (see table
8) to account for variables that will be used during the analysis. See table 8 for simple
statistics reports. Pearson correlation statistics are computed from observations with
non-missing values for each pair of analysis variables. When using the Pearson
correlation coefficient, the correlation coefficient can range in value from −1 to +1. The
larger the absolute value of the coefficient, the stronger the relationship between the
variables. An absolute value of 1 indicates a perfect linear relationship. A correlation
close to 0 indicates no linear relationship between the variables. Table 10 displays a
summary of the analysis.
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Table 12: The CORR Procedure variable table
The CORR Procedure
6 With Variables:

recommend_to_scd awareness_1 knowledge_2 attitudes_3 intention_to_change help_seeking
engagement function aesthetics information age educ_ordinal income_ordinal

7 Variables:

Table 13: The CORR Procedure Simple Statistics
Variable
recommend_to_scd
awareness_1
knowledge_2
attitudes_3
intention_to_change
help_seeking
engagement
function
aesthetics
information
age
educ_ordinal
income_ordinal

N
25
24
24
23
24
24
28
24
25
25
28
28
24

Simple Statistics
Mean
Std Dev
4.44000
0.86987
3.87500
1.48361
3.83333
1.52277
3.86957
1.17954
4.00000
1.10335
4.12500
1.03472
3.74940
0.89198
4.42708
0.60108
3.90000
0.76073
3.96000
0.74833
36.56849
12.17949
3.46429
1.34666
3.25000
2.23120

Median
5.00000
5.00000
5.00000
4.00000
4.00000
4.00000
3.80000
4.62500
4.00000
4.00000
36.25479
3.00000
2.00000

Minimum
3.00000
1.00000
1.00000
1.00000
1.00000
1.00000
1.00000
3.00000
2.50000
2.40000
18.77534
2.00000
1.00000

Maximum
5.00000
5.00000
5.00000
5.00000
5.00000
5.00000
5.00000
5.00000
5.00000
5.00000
58.83562
6.00000
7.00000

Table 14: Spearman Correlation Coefficients – The CORR Procedure

recommend_to_scd

awareness_1

knowledge_2

attitudes_3
intention_to_change
help_seeking

engagement
0.54582
0.0048
25
0.60610
0.0017
24
0.56786
0.0038
24
0.69285
0.0002
23
0.49635
0.0136
24
0.36803
0.0768
24

Spearman Correlation Coefficients
Prob > |r| under H0: Rho=0
Number of Observations
function
aesthetics information
0.71018
0.58993
0.61963
0.0001
0.0019
0.0010
24
25
25
0.26131
0.2284
23
0.18557
0.3966
23
0.31349
0.1554
22
0.31724
0.1402
23
0.20212
0.3550
23

0.52606
0.0083
24
0.44796
0.0281
24
0.49637
0.0160
23
0.52093
0.0091
24
0.36442
0.0800
24
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0.50695
0.0115
24
0.45136
0.0268
24
0.50843
0.0132
23
0.58114
0.0029
24
0.37597
0.0702
24

age
educ_ordinal income_ordinal
_0.01079
0.01074
0.03013
0.9592
0.8863
0.9632
25
25
21
0.06086
0.7776
24
0.14122
0.5104
24
_0.14116
0.5206
23
0.06158
0.7750
24
_0.01397
0.9483
24

_0.05341
0.8042
24
_0.03578
0.8682
24
_0.04050
0.8544
23
0.08693
0.6863
24
_0.07404
0.7310
24

_0.12140
0.6102
20
_0.16201
0.4950
20
_0.13037
0.5838
20
_0.17931
0.4494
20
_0.24146
0.3051
20

Pearson correlation calculation showed several positive and linear correlation between
objective scales (Engagement, Information quality, Functionality, and Aesthetics) and
Sickle cell specific questions. Engagement positively and linearly correlated with the
willingness to share the application with others (R=054582, P>0.05, p=0.0048), Ability
for the application to raise awareness about Sickle Cell Disease (R=0.60610, P>0.05,
p=0.0017) , The ability for the application to increase Sickle Cell Knowledge amongst
users (R=0.56786, P>0.05, p=0.0038) , the ability for the application to increase
attitude towards sickle cell disease care (R=0.69285, P>0.05, p=0.0002), The
application’s ability to increase motivation to change sickle cell disease care
(R=0.49635, P>0.05, p=0.0136) . Positive linear correlations were also found between
Aesthetics and the application’s ability to raise awareness about sickle cell disease
(R=0.52606, P>0.05, p=0.0083), the application’s ability to increase SCD knowledge
(R=0.44796, P>0.05, p=0.0281), the application’s ability to increase attitude to sickle
cell disease care (R=0.49637, P>0.05, p=0.0160) , the ability for the application to
increase motivation to change sickle cell disease care (R=0.52093, P>0.05, p=0.0091).
Positive linear correlations were also observed between the information quality
subscale and the application’s ability to raise awareness (R=0.50695, P>0.05,
p=0.0115), increase sickle cell knowledge (R=0.45136, P>0.05, p=0.0268) , increase
attitude towards SCD care (R=0.50843, P>0.05, p=0.0132) , the ability to motivate
intention to change SCD care (R=0.58114, P>0.05, p=0.0029). Although there were no
statistical significance in the correlation of the application’s functionality and most of the
sickle cell specific questions, a strong linear correlation was found with patient’s
willingness to recommend the application (R=0.71018, P>0.05, p=0.0001). This
correlation was the highest and most statistically significant observation.
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Chapter 6
Discussion & Conclusion
Discussion
Although there are several studies evaluating the use of web-based applications in
medicine, there is currently no published literature evaluating the acceptance and
feasibility of web-based application for adherence to prescribed opioids in SCD.
Therefore, we offer alternative explanations and comparisons of the current results with
past research on cancer and non-cancer pain conditions.
In addition, SCD patient care has a greater focus on not just minimizing pain to the
level of “enough,” but to allow SCD patients to interact in society and the workplace
with independence despite the chronic condition. Many participants emphasized (and
advised other patients of) their need to perform (limited) activity and maintain a wellbeing to minimize the effects of SCD on their lives. Additionally, care for SCD patients
may best be optimized with better medication prescribing behavior, better healthcare
delivery, and better overall support. These factors are often questioned and distrusted
by healthcare teams due to the disparity existing in sickle cell care. The goal of this
study was to develop and test the feasibility of a mobile application for adherence to
prescribed opioids and capture context-specific data associated with prescription opioid
use. This goal was selected with the aim of indirectly bridging the gap of trust between
sickle cell patient and provider. Patients with sickle cell disease are often categorized
as “drug-seekers” because of the high dosage of opioids they need in order to appease
their pain. The recent laws, regulations and attention to opioids prescriptions and
opioids behaviors exacerbated this issue amongst provider thus their reluctance to
prescribe high dose of opioids. Building a web-based application that allowed for
patients to input their pain behavior is one way that the VCUhealth system was able to
improve care for sickle cell patients. This software allowed patients to document, their
opioids intake behavior and their pain rating and evaluating if the software as a means
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of communication was accepted and welcomed in the sickle cell community as a way of
building trust and establishing report with the care team. The majority of users in our
study possessed an Android device (64%) vs iPhones (36%).
The MARS tool, a reliable, multidimensional measure for trialing, classifying, and rating
the quality of mobile health apps was used to evaluate the quality of our application.
The evaluation was divided into categories including: Engagement, Functionality,
Aesthetics, and Information Quality. Each section was scored according to the MARS
tool scoring guide by calculating each one of the above-named scales means and the
overall mean app quality total score. The application’s functionality rated highest
(M=4.54, SD= 0.66) followed by engagement (M=3.93, SD=0.73), aesthetics (M=3.92,
SD=0.81), and information quality (M=3.91, SD=0.87). The overall mean app quality
total score was M=3.98, SD=0.77. These means are reported on a scale of 1 to 5 with 1
being the poorest quality and 5 being the greatest quality.
These results trendily mirrored those reported in a review and content analysis of
engagement, functionality, aesthetics, information quality, and change techniques in the
most popular commercial apps for weight management using the MARS tool. Bardus et
al reported using the tool to independently assess 23 popular app’s features, quality
and content. Their reported results were: Engagement (M=3.0, SD=0.9), Functionality
(M=3.8, SD=0.9), Aesthetics (M=3.4, SD=1.2) and information Quality (M=2.2, SD=0.7)
with a total score (M=3.1, SD=0.8) 56. An emerging trend with functionality leading in
rating scores is observed between our study and their review although our overall
performance per category is superior. These results indicate a high internal
consistency and speak to the quality of the application that was developed. The
application acceptance was analyzed by using the COOR procedure to find relationship
between the objective subscales (Engagement, functionality, Aesthetics and
Information quality) and subjective sickle cell specific questions. The app quality
indicated by MARS scores was positively correlated with number of subjective sickle
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cell specific topics. The Highest positive linear correlation was found between the
application’s functions and the willingness for participants to recommend the application
to other sickle cell patients (R=0.71018, P>0.05, p=0.0001). There were no
relationships found between age, income and education and any of the sickle cell
specific subjective measures indicating no bias due to age, income or level of education
in the application’s rating using the MARS tool. Although no studies are without
limitations, these results highlight the feasibility of a mobile software application as a
mean of measure of adherence and context specific information surrounding Sickle Cell
patients medication intake behavior and their self-reported pain.
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Conclusion
The current technology driven world ruled by apps, interconnectivity and
communications begs for the need of more disease-oriented web-based applications.
Although large number of medication reminder apps are available in the app stores, the
majority of them aim to cover a broad spectrum of disease and lack the specific focus
on one disease which often only gives a snapshot or birds eye view into a patient’
medication intake behavior. The goal of this project was to develop and test the
acceptability of an application developed for a specific group or type of patients to help
improve adherence to their opioids intake. Results showed that the application worked
well and was well received in the targeted population. Engagement scores were also
elevated indicating that patients increasingly want to become more engaged in their
own health care, and with patient specific applications such as the we designed and
used for this project, we give our patients the ability to positively impact their behaviors,
improve their adherence, bridge the gap of trust between patient and provider and
impact their overall health. These findings however could be biased according to the
Hawthorne effect. The Hawthorne effect refers to the inclination of some people to work
harder and perform better when they are being observed as part of an experiment.
When transposed in a clinical research environment, this indicates that positive results
could be due to the simple fact that participants are aware that they are being
observed. The Hawthorne effect was evaluated in a randomized controlled trial were
researchers aimed to compare minimal follow-up to intensive follow-up in participants in
a placebo controlled trial of Ginkgo biloba for treating mild-moderate dementia and
found that more intensive follow-up of individuals resulted in a better outcome than
minimal follow-up, as measured by their cognitive functioning 57. The bias generated by
the Hawthorne effect pushes us to consider longitudinal evaluation with minimal
intervention in future work when evaluating medial health applications. Our Study
focused on evaluating the application’s quality, future work should consider adding a
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verification mechanism to validate the self-reported entries. Potential verification
mechanisms could be items such as the newly FDA approved digital pill — a
medication embedded within and ingestible sensor that could provide objective
verification of medication adherence.
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Appendix
Appendix 1: Interview Guide

Semi-Structure Interview Guide
Project Title: Understanding Adherence to Prescribed Opioids in Sickle Cell Disease
Arrival
Welcoming patient and having some informal chat in order to put them in their ease and make
them feel comfortable. Opening Questions: How are you today? How is [school] [Work]?
“Please tell us your first and last name.”
The following statement is to be read to the participants before each interview.
“Thank you so much for agreeing to participate in this study. What we would like to do today is
talk about issues connected with sickle cell disease pain. We will be discussing how you manage
your pain, drawing on your experiences. We want to learn from you to help other people in the
future. We have a number of areas we would like to cover, including how patients use their
medicine and other ways of pain control. At any time if you think of any comments or
experiences, we would very much like to hear them, even if that’s not what we are talking about
right then. We want to understand the different ways people cope with their pain.”
Introduction
Medication adherence: “As I mentioned before, the first thing we will ask you is a series of
questions about your experience with pain and how it made you feel. Then we will ask you a
series of questions about how patients take their prescribed pain medicines. I am interested in
things that people do that affect their ways of taking their pain medicines. The purpose of the
study is not to judge whether your ways of taking pain medicine are good or bad. The purposes
of the study are to just learn exactly how pain affects you and what you do about it. That
includes what medicines you take, and how you take them, regardless of how they are
prescribed. Please try and answer each question with as much detail as possible.”
Sickle Cell Anemia and Pain (generally)
1) Beginning the interview: I'd like to start out this interview by hearing a little bit about your
experiences with Sickle Cell Disease. Can you tell me how you usually experience your
disease?
Probe:
a) How has your sickle cell disease pain affected your personal life? Think about when you
are in pain–during that time, how are your family, life style, daily activities affected?
2) Please tell me all the medical problems that cause you pain.
Explore:
a) Follow-up questions (f/u): Of all the problems you have that are causing you pain, which
one is the worst?
3) What medicines are you currently taking for your pain? (Please tell me all you can
remember, regular or occasional, prescription or over the counter).
Explore:
a. (f/u): How well do these medicines work for you?
In the following questions, I would like to know about how you use your strong pain
medicine like Morphine, MS Contin, Tramadol, Tylenol III, Codeine, Darvocet,
propoxyphene, Percocet, OxyContin, oxycodone, Vicodin, Lortab, hydrocodone, Dilaudid,
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hydromorphone, or Pain patches (Fentantl), prescribed by a doctors. But from now on I will
just say pain medicine for strong pain medicine. Let’s talk now about that.
Adherence to Prescribed Opioid: To Identify Actual Behavior of Use
4) It sounds like you are taking (select appropriate phrase according to above) [both] [shortacting] [and] [long-acting] to manage your pain. Thinking back over the last 30 days, how
did you use your pain medicine?
Probes:
a. Do you usually use as needed and/or scheduled pain medicine every day?
b. How often do you take them? How many pills do you take each time? How many
times are you supposed to take pills each day?
Explore:
a. Typically, how long do you wait to take your next dose of pain medication?
What factors influence your decision?
b. How long does it take you to get comfortable after taking your medication?
c. Do you ever take your medicine in a different order or dosage than prescribed by
your doctor? Why? What factors influence your decision?
d. Have you ever stopped using your medicine for any reason? Can you tell me a
little bit about that?
Reasons for Underuse, Overuse, Erratic, and Quitting
5) The following questions below depend on answer to this question # 4) [For Adherent what
was it that made you want to keep taking your pain medicine as prescribed?] [For Nonadherent: Why did you decide that you wanted to quit using your pain medicine?] [For
Erratic User: You mention that you sometimes use more and sometime use less of your pain
medications that your doctor than prescribed of your strong pain medicines; what is the
reason? What made you use it that way?]
6) I know that many doctors prefer to treat sickle cell pain with a combination of as-needed and
scheduled pain medicine or a number of different medicines at the same time. How do you
know which kinds of medicine to use? How did you decide to take them?
7) Besides using your pain medicine to help with pain, what other methods do you use, such as
home remedies?
Explore:
a. (f/u) If you use more than one method, how do you choose which one to use when?
How do you combine methods?
8) Thinking about a typical day (with pain or without pain), tell me how you usually take your
prescriptions during that 24 hour period.
Probes:
a. When do you usually take your pills?
b. Are there any times of day (or night) when you take more or less of your
medications?Why?
c. How would your medication usage vary on an atypical (unusual) day? What does an
atypical day look like for you? Why would you change the way you use your
medicine?
9) Do you agree with the amount of pain medicine your doctor prescribes for your sickle cell
pain?
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Probes:
a. Do you think that your doctor has you on the right medicines?
b. What changes would you make to your drug regimen if it were up to you?
10) Regimen Complexity Do you take your pain medication the way that your doctor originally
prescribed it? Have you ever had any problems understanding how to take your
medications? (If so) Tell more me about it.
General Factors Affect Adherence (Motivations and Difficulties) Over the Time or
Episodically
Transition: Next, I would like to ask you some questions about your experiences with pain
medicine
11) Motivations or Factors for Use: What factor influence, encourage, or motivate you to use
your pain medicine (scheduled pain medicine or as-needed pain medicine)?
12) Barriers, Challenges or Difficulties of Adherence to Pain Medicine at Home: Sometimes
SCD adults find it difficult to take medicines as the doctor has ordered. What are some
things that make it difficult to continue taking your pain medicines as prescribed? Why?
Explore:
a. (f/u) Describe a time when you experienced difficulty taking your scheduled or asneeded pain medicine. How did these challenges affect your ways of using pain
medicine?
13) Family or Friends Concern of Opioid Use: Think of your environment. By environment I
mean the physical and social world around you. How does your environment affect the way
you take your medicine?
Probe:
a. How do your family and friends affect how you take (or don’t take) your pain
medicine? Share with us about how people in your life play a role in taking your
medicine?
b. (f/u) How does society affect how you take your pain medicine? Do you feel you
must be “responsible” to yourself or to others?
c. How does the weather affect how you take your pain medicine? If you can, share
with us what kinds of weather change the way you take your pain medicine.
14) Reasons for Underuse: There are many reasons why SCD patients use less pain medicine
than prescribed, don’t use pain medicine for a time, or choose not to use it. Thinking about
the last three months, please tell me a story of a time when you took less of your medicine
than you usually take or took less than you thought you needed?
Explore:
a. (f/u) What were the reasons for each of the times that you needed/wanted to use pain
medicine, but didn’t use? Describe those reasons in detail.
15) Reasons for Overuse: There are many reasons why SCD patients use more pain medicine
than prescribed or there are times when they don’t need or want to use pain medicine, but
they choose to use it anyway. Thinking about the last three months, please tell me a story of
a time when you took more of your medicine than you usually take or took more than you
thought you needed?
Explore:
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a. (f/u) What were the reasons for each of the times that you didn’t need/want to use
pain medicine, but used more or used it anyway? Describe those reasons in detail.
Using Opioid for Symptoms/Reasons Other than Pain
16) Some SCD patients may use pain medicine for reasons other than pain. Thinking about the
last three months, please tell me a story of a time you used your pain medicine for reasons or
symptoms other than pain. How would you describe these reasons?
17) Forget or Missing Doses: People have a lot of different feelings about how medicines work
and what the results are if they miss a dose. Thinking about the last three months, please tell
me a story of a time you missed a dose or several doses of pain medicine.
Explore:
a. (f/u) How did you feel you when you missed a pill or several pills?
b. (f/u) How important is it to you to take your medicines as prescribed? Please
explain.
c. (f/u) What do you do when you realize you miss/forget to take a dose of your
prescribed medicines? Take more, take less? Describe.
Reasons for Episodic and Temporary Change in Adherence
Using Opioid while in Pain when Feeling Worse than Usual
18) Think back to when you were feeling worse pain than usual or when you having crises.
What, if anything, did you do differently to get rid of your pain?
Explore:
a. Why do you think you chose to use your pain medicine in this way, in this situation?
b. (f/u) What did you do when the pain was not relieved (you were still feeling pain)
after you took your pain medicines? Did you use your pain medicine differently then?
Did you use more or less than prescribed?
c. (f/u) What made you decide to use the medicine in such a way?
d. (f/u) Did the location of pain affect your way of using pain medicine?
Using Opioid while in Pain when Feeling Good
19) When you are feeling good, how do you use your medicine?
20) Think back when you are/were feeling better after you took your pain medicines, how did
you use your medicine then?
Probes:
a. Did you ever stop taking your scheduled or as-needed medicines when you were
feeling good? If so, tell more about that.
21) Describe a time for me when you were having no/little SCD pain (or you felt better) but still
chose to take more pain medicine?
Explore:
a. (f/u) Why do you think you chose to use your pain medicine in this way, in the
situation you explained to me?
Psychosocial Factors
Using Opioid while in Pain and Having Social Activities, Special Events, Circumstances, or
Situation
22) How do you use your pain medicine before, after, or during some special social event,
activity or special situation?
Explore:
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a. (f/u) To what extent are you able to use your medicine as prescribed during this
time? Do you change your routine?
Using Opioid while in Pain and Having Stress or Other Psychological Components
23) How does stress in your life relate to your pain? Which usually comes first, the stress or the
pain?
Explore:
a. (f/u) How do you cope with the stress when you are in pain?
b. (f/u) Do you change your routine (I mean the way in which you take your medicine)
when you are in stress and in pain?
c. (f/u) Do you change how you use your pain medicine when you are under stress?

Ending the Interview
24) Recommendations: Based on your experience, what information do you think is important
for other patients and healthcare providers to know about pain medicine?
Probes:
a. What advice would you give a person who is considering maintaining his/ her pain
medicine as prescribed or improving his /her way of taking pain medicine?
To wrap up: We have come to the end of the interview. You explained before how you use
your pain medicine and the reasons for using them. In light of what we have just been
discussing (medicine use and reasons for use), I’d like to ask you if you have any additional,
final comments, or anything that you think we should have talked about but didn’t? This
concludes ends the interview. As we conclude, I would like to thank you for your assistance
with this research project. You have been most helpful in responding to the questions. Thank
you for taking part in this interview and for responding to the questions so thoroughly. I
appreciate your time, interest, and openness. How do you feel about the interview we have
just had? May I call you if I need to clarify or add to any information you have provided? Is
there anything that you would like to ask me? I am happy to answer any questions that you
may have.
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Appendix 2: MARS Application rating scale

Patient feedback survey
Adapted from the Mobile Application Rating Scale (MARS)
Patient ID:
The Classification section is used to collect descriptive and technical
information about the app.
App Name:
Platform:

OPpil
 iPhone

 iPad

 Android

Brief description:

Focus: What do you
think that this APP is
designed to do?
(select all that apply)














In your opinion, why are
we conducting this
research study?
(all that apply)
 Assessment
 Feedback
 Information/Education
 Tracking
 Goal setting
 Advice /Tips /Strategies /Skills
training
 CBT - Behavioural (positive
events)
 CBT – Cognitive (My

Makes me feel happy/Healthy
Helps me Relax
Reduce negative emotions
Depression
Anxiety/Stress
Anger
Behavior Change
Alcohol /Substance Use
Helps me set goals
It Entertains me/Distracts me
Relationships
Physical health
Other

Thoughts)

 ACT -

Acceptance commitment
therapy 
Mindfulness/Meditation
 Relaxation
 Gratitude
 Strengths based
 Other

Affiliations: To the best of your knowledge, this research is associated with
which one of these?
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 Unknown
 University

 Commercial

 Government

Please select the
age group in which
you belong

 NGO

Technical aspects of app (all
that apply)
 Allows sharing (Facebook,
Twitter, etc.)
 Has an app community
 Allows password-protection
 Requires login
 Sends reminders
 Needs internet to function

 Children
(under 12) 
Adolescents (1317)  Young
Adults (18-25) 
Adults
 General
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App Quality Ratings
The Rating scale assesses app quality on four dimensions. All items are rated on a
5-point scale from “1.Inadequate” to “5.Excellent”. Circle the
number that most accurately represents the quality of the app
component you are rating. Please use the choices provided for
each response category.
SECTION A
Engagement – fun, interesting, customizable, interactive (e.g. sends
alerts, messages, reminders, feedback, enables sharing), welltargeted to audience
1. Entertainment: Is the app fun/entertaining to use?
1
Dull, not fun or entertaining at all
2
Mostly boring
3
OK, fun enough to entertain user for a brief time (< 5 minutes)
4
Moderately fun and entertaining, would entertain user for some time
(5-10 minutes total)
5
Highly entertaining and fun, would stimulate repeat use
2. Interest: Is the app interesting to use?
1
Not interesting at all
2
Mostly uninteresting
3
OK, neither interesting nor uninteresting; would engage user for a
brief time (< 5 minutes)
4
Moderately interesting; would engage user for some time (5-10
minutes total)
5
Very interesting, would engage user in repeat use
3. Customization: Does it provide/retain all necessary
settings/preferences for apps features (e.g. sound, content,
notifications, etc.)?
1
Does not allow any customization or requires setting to be input
every time
2
Allows insufficient customization limiting functions
3
Allows basic customization to function adequately
4
Allows numerous options for customization
5
Allows complete tailoring to the individual’s
characteristics/preferences, retains all settings
4. Interactivity: Does this app allow user input, provide feedback,
contain prompts (reminders, sharing options, notifications, etc.)?
1

No interactive features and/or no response to user interaction
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2
Insufficient interactivity, or feedback, or user input options, limiting
functions
3
Basic interactive features to function adequately
4
Offers a variety of interactive features/feedback/user input options
5
Very high level of responsiveness through interactive
features/feedback/user input options
5. Target group: Is the app content (visual information, language,
design) appropriate for sickle cell patients?
1
Completely inappropriate/unclear/confusing
2
Mostly inappropriate/unclear/confusing
3
Acceptable but not targeted. May be
inappropriate/unclear/confusing
4 Well-targeted, with negligible issues
5
Perfectly targeted, no issues found
A. Engagement mean score =
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SECTION B
Functionality – app functioning, easy to learn,
navigation, flow logic, and gestural design of app
6.

Performance: How accurately/fast do the app features
(functions) and components
(buttons/menus) work?
1
App is broken; no/insufficient/inaccurate response (e.g.
crashes/bugs/broken features, etc.)
2
Some functions work, but lagging or contains major technical
problems
3
App works overall. Some technical problems need fixing/Slow at
times
4
Mostly functional with minor/negligible problems
5
Perfect/timely response; no technical bugs found/contains a ‘loading
time left’ indicator

7. Ease of use: How easy is it to learn how to use the app; how clear are
the menu labels/icons and instructions?
1
No/limited instructions; menu labels/icons are confusing;
complicated
2
Useable after a lot of time/effort
3
Useable after some time/effort
4
Easy to learn how to use the app (or has clear instructions)
5
Able to use app immediately; intuitive; simple
8. Navigation: Is moving between screens
logical/accurate/appropriate/ uninterrupted; are all necessary
screen links present?
1 Different sections within the app seem logically disconnected and
random/confusing/navigation is difficult
2
Usable after a lot of time/effort
3
Usable after some time/effort
4
Easy to use or missing a negligible link
5
Perfectly logical, easy, clear and intuitive screen flow throughout, or
offers shortcuts
9. Gestural design: Are interactions (taps/swipes/pinches/scrolls)
consistent and intuitive across all components/screens?
1
2
3

Completely inconsistent/confusing
Often inconsistent/confusing
OK with some inconsistencies/confusing elements
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4
5

Mostly consistent/intuitive with negligible problems
Perfectly consistent and intuitive

B. Functionality mean score =

SECTION C
Aesthetics – graphic design, overall visual appeal, color scheme, and
stylistic consistency
10. Layout: Is arrangement and size of buttons/icons/menus/content
on the screen appropriate or zoom able if needed?
1 Very bad design, cluttered, some options impossible to
select/locate/see/read device display not optimized
2
Bad design, random, unclear, some options difficult to
select/locate/see/read
3 Satisfactory, few problems with selecting/locating/seeing/reading
items or with minor screen- size problems
4
Mostly clear, able to select/locate/see/read items
5 Professional, simple, clear, orderly, logically organized, device
display optimized. Every design component has a purpose
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11. Graphics: How high is the quality/resolution of graphics used for
buttons/icons/menus/content?
1 Graphics appear amateur, very poor visual design disproportionate, completely stylistically inconsistent
2 Low quality/low resolution graphics; low quality visual design –
disproportionate, stylistically inconsistent
3
Moderate quality graphics and visual design (generally consistent in
style)
4
High quality/resolution graphics and visual design – mostly
proportionate, stylistically consistent
5 Very high quality/resolution graphics and visual design proportionate, stylistically consistent throughout
12. Visual appeal: How good does the app look?
1
No visual appeal, unpleasant to look at, poorly designed,
clashing/mismatched colors
2
Little visual appeal – poorly designed, bad use of color, visually
boring
3
Some visual appeal – average, neither pleasant, nor unpleasant
4
High level of visual appeal – seamless graphics – consistent and
professionally designed
5
As above + very attractive, memorable, stands out; use of color
enhances app features/menus
C. Aesthetics mean score =
SECTION D
Information – Contains high quality information (e.g. text, feedback,
measures, references)
from a credible source. Select N/A if the app component is irrelevant.
13. Accuracy of app description (in app store): Does app
contain what is described?
1
Misleading. App does not contain the described
components/functions. Or has no description
2
Inaccurate. App contains very few of the described
components/functions
3
OK. App contains some of the described components/functions
4
Accurate. App contains most of the described components/functions
5
Highly accurate description of the app components/functions
14. Goals: Does app have specific, measurable and achievable
goals (specified in app store description or within the app
itself)?
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N/A Description does not list goals, or app goals are irrelevant to
research goal (e.g. using a game for educational purposes)
1
App has no chance of achieving its stated goals
2
Description lists some goals, but app has very little chance of
achieving them
3
OK. App has clear goals, which may be achievable.
4
App has clearly specified goals, which are measurable and
achievable
5
App has specific and measurable goals, which are highly likely to be
achieved
15. Quality of information: Is app content correct, well written, and
relevant to Sickle Cell disease ?
N/A There is no information within the app
1
Irrelevant/inappropriate/incoherent/incorrect
2
Poor. Barely relevant/appropriate/coherent/may be incorrect
3
Moderately relevant/appropriate/coherent/and appears correct
4
Relevant/appropriate/coherent/correct
5
Highly relevant, appropriate, coherent, and correct
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16. Quantity of information: Is the amount of information in the App
complete?
N/A There is no information within the app
1
Minimal or overwhelming
2
Insufficient or possibly overwhelming
3
OK but not comprehensive or concise
4 Offers a broad range of information, has some gaps or
unnecessary detail; or has no links to more information and
resources
5
Comprehensive and concise; contains links to more information and
resources
17. Visual information: Can you understand the images displayed within
the App?
N/A There is no visual information within the app (e.g. it only contains
audio, or text)
1
Completely unclear/confusing/wrong or necessary but missing
2
Mostly unclear/confusing/wrong
3
OK but often unclear/confusing/wrong
4
Mostly clear/logical/correct with negligible issues
5
Perfectly clear/logical/correct

D. Information mean score =

*

* Exclude questions rated as “N/A” from the mean score calculation.
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App subjective quality
SECTION E
20. Would you recommend this app to people with sickle cell disease?
1 Not at all
2
3 Maybe
4
5 Definitel

I would not recommend this app to
There are very few people I would
There are several people whom I would
There are many people I would
I would recommend this app to everyone

21. How many times do you think you would use this app in the next 12
months if it was relevant to you?
1
2
3
4
5

None
1-2
3-10
10-50
>50

22. Would you pay for this app?
1
No
Maybe
3
5
Yes
23. What is your overall star
rating of the app?
1
2
3
4
5







One of the worst apps I’ve used
Average
One of the best apps I've used

Scoring
App quality scores for
SECTION
A: Engagement Mean Score =
B: Functionality Mean Score =
C: Aesthetics

Mean Score =

D: Information Mean Score =
App quality mean Score

=
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App subjective quality Score =
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App-specific
These added items can be adjusted and used to assess the perceived impact of the app on the
user’s knowledge, attitudes, intentions to change as well as the likelihood of actual change in the
target health behavior.
SECTION F
1.
Awareness: This app is likely to increase awareness of the importance of
addressing Sickle Cell disease
Strongly
1

2

3

4

Strongly
5

2. Knowledge: This app is likely to increase knowledge/understanding of Sickle
cell disease
Strongly
1

2

3

4

Strongly
5

3.
Attitudes: This app is likely to change attitudes toward improving Sickle cell
disease
Strongly
1

2

3

4

Strongly
5

4. Intention to change: This app is likely to increase intentions/motivation to
address Sickle cell disease
Strongly
1

2

3

4

Strongly
5

5. Help seeking: Use of this app is likely to encourage further help seeking for
sickle cell disease
Strongly
1

2

3

4

Strongly
5

6. Behavior change: Use of this app is likely increase/decrease sickle cell
disease
Strongly
1

2

3
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4

Strongly
5
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In order to comply with federal regulations, industry standards, and the terms of this approval, the
investigator must (as applicable):
1. Conduct the research as described in and required by the Protocol.
2. Obtain informed consent from all subjects without coercion or undue influence, and provide
the potential subject sufficient opportunity to consider whether or not to participate (unless
Waiver of Consent is specifically approved or research is exempt).
3. Document informed consent using only the most recently dated consent form bearing the
VCU IRB “APPROVED” stamp (unless Waiver of Consent is specifically approved).
4. Provide non-English speaking patients with a translation of the approved Consent Form in
the research participant's first language. The Panel must approve the translated version.
5. Obtain prior approval from VCU IRB before implementing any changes whatsoever in the
approved protocol or consent form, unless such changes are necessary to protect the safety
of human research participants (e.g., permanent/temporary change of PI, addition of
performance/collaborative sites, request to include newly incarcerated participants or
participants that are wards of the state, addition/deletion of participant groups, etc.). Any
departure from these approved documents must be reported to the VCU IRB immediately as
an Unanticipated Problem (see #7).
6. Monitor all problems (anticipated and unanticipated) associated with risk to research
participants or others.
7. Report Unanticipated Problems (UPs), including protocol deviations, following the VCU IRB
requirements and timelines detailed in VCU IRB WPP VII-6:
8. Obtain prior approval from the VCU IRB before use of any advertisement or other material
for recruitment of research participants.
9. Promptly report and/or respond to all inquiries by the VCU IRB concerning the conduct of
the approved research when so requested.
10. All protocols that administer acute medical treatment to human research participants must
have an emergency preparedness plan. Please refer to VCU guidance on
http://www.research.vcu.edu/human_research/guidance.htm.
11. The VCU IRBs operate under the regulatory authorities as described within:
a. U.S. Department of Health and Human Services Title 45 CFR 46, Subparts A, B, C, and
D (for all research, regardless of source of funding) and related guidance documents.
b. U.S. Food and Drug Administration Chapter I of Title 21 CFR 50 and 56 (for FDA
regulated research only) and related guidance documents.
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